Advanced Enzyme Technologies Ltd (IN:ADVENZYMES)
:ADVENZYMES
Want to see IN:ADVENZYMES full AI Analyst Report?
ADVENZYMES Stock Chart & Stats
₹303.25
-₹1.10(-0.32%)
At close: 4:00 PM EST
₹303.25
-₹1.10(-0.32%)
Day’s Range― - ―
52-Week Range₹251.90 - ₹366.55
Previous CloseN/A
Volume535.87K
Average Volume (3M)13.78K
Market Cap
₹37.72B
Enterprise Value₹37.53B
Total Cash (Recent Filing)₹6.19B
Total Debt (Recent Filing)₹346.54M
Price to Earnings (P/E)19.9
Beta1.15
Next Earnings
May 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.7%
Share Statistics
EPS (TTM)2.80
Shares Outstanding111,926,800
10 Day Avg. Volume10,375
30 Day Avg. Volume13,779
Financial Highlights & Ratios
PEG Ratio-13.34
Price to Book (P/B)2.27
Price to Sales (P/S)5.07
P/FCF Ratio28.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)15.5
Revenue Forecast (FY)₹8.54B
Bulls Say, Bears Say
Bulls Say
Consistent Revenue And Profit GrowthSustained top-line and earnings growth across reporting periods indicates durable demand for enzyme and probiotic products in multiple end-markets. Recurring consumable use by B2B customers supports predictable revenues and underpins medium-term expansion and reinvestment capacity.
High And Sustainable Profit MarginsStrong gross and net margins reflect differentiated formulations and pricing power in specialty enzyme markets. High margins support internal funding for R&D, steady cash generation and resilience to input cost variability, helping preserve operating profitability over time.
Conservative Balance Sheet With Very Low LeverageMinimal financial leverage and a high equity ratio reduce solvency risk and provide flexibility to fund capex, scale fermentation capacity, or pursue M&A. A conservative capital structure supports stability through cycles and enables strategic investments without refinancing pressure.
Bears Say
Slight Decline In EBIT MarginA falling EBIT margin, even if modest, signals potential stresses in operating efficiency or margin mix that can erode operating leverage over time. If not addressed through productivity or pricing actions, it could constrain free cash available for growth and R&D investments.
Modest Free Cash Flow GrowthWhile operating cash generation and FCF-to-net-income are favorable, slow free cash flow growth limits the pace at which the company can scale production, invest in new strains or formulations, or increase shareholder returns without external financing.
Return On Equity Below Industry LeadersA mid-single-digit ROE gap versus top peers suggests the company may be less efficient at converting equity into returns. Improving asset utilization, product mix or margin expansion is needed to lift shareholder returns to peer levels over the medium term.
Advanced Enzyme Technologies Ltd News
ADVENZYMES FAQ
What was Advanced Enzyme Technologies Ltd’s price range in the past 12 months?
Advanced Enzyme Technologies Ltd lowest stock price was ₹251.90 and its highest was ₹366.55 in the past 12 months.
What is Advanced Enzyme Technologies Ltd’s market cap?
Advanced Enzyme Technologies Ltd’s market cap is ₹37.72B.
When is Advanced Enzyme Technologies Ltd’s upcoming earnings report date?
Advanced Enzyme Technologies Ltd’s upcoming earnings report date is May 14, 2026 which is in 14 days.
How were Advanced Enzyme Technologies Ltd’s earnings last quarter?
Advanced Enzyme Technologies Ltd released its earnings results on Jan 31, 2026. The company reported ₹2.8 earnings per share for the quarter, beating the consensus estimate of N/A by ₹2.8.
Is Advanced Enzyme Technologies Ltd overvalued?
According to Wall Street analysts Advanced Enzyme Technologies Ltd’s price is currently Overvalued.
Does Advanced Enzyme Technologies Ltd pay dividends?
Advanced Enzyme Technologies Ltd pays a Quarterly dividend of ₹1.2 which represents an annual dividend yield of 1.7%. See more information on Advanced Enzyme Technologies Ltd dividends here
What is Advanced Enzyme Technologies Ltd’s EPS estimate?
Advanced Enzyme Technologies Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Advanced Enzyme Technologies Ltd have?
Advanced Enzyme Technologies Ltd has 111,926,800 shares outstanding.
What happened to Advanced Enzyme Technologies Ltd’s price movement after its last earnings report?
Advanced Enzyme Technologies Ltd reported an EPS of ₹2.8 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 6.825%.
Which hedge fund is a major shareholder of Advanced Enzyme Technologies Ltd?
Currently, no hedge funds are holding shares in IN:ADVENZYMES
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Advanced Enzyme Technologies Ltd
Advanced Enzyme Technologies Limited researches and develops, manufactures, and markets enzymes and probiotics in India, the United States, Asia, Europe, and internationally. The company offers enzymes for human healthcare and animal nutrition, fruit and vegetable processing, baking, brewing, and malting, and grain processing, protein modification, yeast processing, dairy and cheese processing, and oils and fats processing, as well as for specialty applications. It also provides non-food processing enzymes for textile processing, leather, pulp and paper, detergents and cleaning aids, bio-fuels, and biocatalysis. The company was formerly known as Advanced Biochemicals Limited and changed its name to Advanced Enzyme Technologies Limited in 2005. Advanced Enzyme Technologies Limited was founded in 1957 and is based in Thane, India.
Technical Analysis
Dishman Carbogen Amcis Ltd.
―
Gufic Biosciences Limited
―
Morepen Laboratories Limited
―
RPG Life Sciences Limited
―
―